Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Pharm ; 517(1-2): 359-372, 2017 Jan 30.
Article in English | MEDLINE | ID: mdl-28007545

ABSTRACT

Pharmacokinetics of cisplatin administered by the pulmonary route were established in mice using dry powders inhaler (DPI) formulations showing immediate (F1) and controlled release (CR, solid lipid microparticles) in vitro, without (F2) or with PEGylated excipients (F3, F4). Formulation administration was realized using dry powder blends (correspondingly named thereafter F1B to F4B) able to reproducibly deliver particles in vivo using a DP-4M Dry Powder Insufflator™. Their platinum pharmacokinetics were established over 48h in lungs, total blood and non-target organs vs. IV and endotracheal nebulization (EN). EN and F1B were rapidly distributed from the lungs (t1/2i 2.6 and 5.0min). F2B was eliminated in ∼1h (t1/2i 9.0min). F3B lung retention was sustained for ∼7h (t1/2i 59.9min), increasing lung AUC 11-, 4- and 3-fold vs. IV, F1B and F2B. Total blood tmax were higher and AUC and Cmax lower using the pulmonary route vs. IV. Kidney Cmax was reduced 6-, 2- and 3-fold for F1B, F2B and F3B. AUC in kidneys were 2- to 3-fold lower for F1B and F2Bvs. IV but comparable for IV vs. F3B, probably because of kidney saturation. PEGylated solid lipid microparticles provided cisplatin particles with interesting lung retention and CR properties.


Subject(s)
Lung/metabolism , Platinum/pharmacokinetics , Powders/chemistry , Administration, Inhalation , Administration, Intravenous , Animals , Cisplatin/administration & dosage , Cisplatin/chemistry , Delayed-Action Preparations/chemistry , Delayed-Action Preparations/pharmacokinetics , Drug Liberation , Dry Powder Inhalers , Female , Kidney/metabolism , Mice , Particle Size , Platinum/blood , Polyethylene Glycols/chemistry , Powders/administration & dosage , Rheology
2.
Int J Pharm ; 515(1-2): 209-220, 2016 Dec 30.
Article in English | MEDLINE | ID: mdl-27737810

ABSTRACT

The present study focuses on the development of dry powders for inhalation as adjuvant chemotherapy in lung cancer treatment. Cisplatin was chosen as a potential candidate for a local treatment as it remains the main platinum component used in conventional chemotherapies, despite its high and cumulative systemic toxicities. Bulk cisplatin was reduced to submicron sizes using high-pressure homogenization, mixed with a solubilized lipid and/or PEGylated component and then spray-dried to produce controlled-release dry powder formulations. The obtained formulations were characterized for their physicochemical properties (particle size and morphology), aerodynamic performance and release profiles. Cisplatin content and integrity were assessed by electrothermal atomic absorption spectrometry and 195Pt nuclear magnetic resonance spectroscopy. DPI formulations with cisplatin contents ranging from 48.5 to 101.0% w/w exhibited high fine particle fractions ranging from 37.3% to 51.5% of the nominal dose. Formulations containing cisplatin microcrystals dispersed in solid lipid microparticles based on acceptable triglycerides for inhalation and PEGylated excipients showed a controlled-release for more than 24h and a limited burst effect. These new formulations could provide an interesting approach to increasing and prolonging drug exposure in the lung while minimizing systemic toxicities.


Subject(s)
Cisplatin/administration & dosage , Cisplatin/chemistry , Delayed-Action Preparations/administration & dosage , Delayed-Action Preparations/chemistry , Lung Neoplasms/drug therapy , Powders/administration & dosage , Powders/chemistry , Administration, Inhalation , Chemistry, Pharmaceutical/methods , Desiccation/methods , Drug Compounding/methods , Dry Powder Inhalers/methods , Excipients/chemistry , Particle Size , Polyethylene Glycols/chemistry , Solubility
3.
Eur J Pharm Biopharm ; 86(1): 46-54, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23523546

ABSTRACT

Three Itraconazole (ITZ) dry powders for inhalation (DPI) were prepared by spray-drying a mannitol solution in which the ITZ was in suspension (F1) or was in solution without (F2) or with phospholipid (PL) (F3). These powders were endotracheally insufflated in vivo at a single dose of 0.5mg/kg for pharmacokinetic profile (lung and plasma concentration) determination in ICR CD-1 mice. ITZ was crystalline in F1 and assumed to be amorphous in the F2 and F3 formulations. F2 and F3 formulations allowed the in vitro formation of an ITZ supersaturated solution with a maximum solubility of 450±124ng/ml (F2) and 498±44ng/ml (F3), in contrast to formulation F1 (<10ng/ml). As a result of these higher solubilities, absorption into the systemic compartment after endotracheal administration was faster for formulations F2 and F3 (shorter tmax) and in larger quantities compared to the F1 formulation (plasmatic AUC0-24h of 182ngh/ml, 491.5ngh/ml and 376.8ngh/ml, and tmax of 60min, 30min and 5min for F1, F2 and F3, respectively). PL increased the systemic bioavailability of ITZ (determined by the AUCplasma to AUClung ratio) as a consequence of their wetting and absorption enhancement effect. ITZ lung concentrations after pulmonary administration remained higher than the targeted dose, based on the minimal inhibitory concentrations for Aspergillus fumigatus (2µg/glung), 24h post-administration for both F1 and F2 formulations. However, this was not the case for formulation F3, which exhibited a faster elimination rate from the lung, with an elimination half-life of 4.1h vs. 6.5h and 14.7h for F1 and F2, respectively.


Subject(s)
Antifungal Agents/administration & dosage , Antifungal Agents/pharmacokinetics , Itraconazole/administration & dosage , Itraconazole/pharmacokinetics , Lung/metabolism , Animals , Antifungal Agents/blood , Antifungal Agents/chemistry , Aspergillus fumigatus/drug effects , Biological Availability , Chemistry, Pharmaceutical , Crystallization , Drug Compounding , Dry Powder Inhalers , Half-Life , Itraconazole/blood , Itraconazole/chemistry , Male , Mice , Mice, Inbred ICR , Microbial Sensitivity Tests , Particle Size , Powders , Solubility , Surface Properties , Tissue Distribution
4.
Eur J Pharm Biopharm ; 81(3): 627-34, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22538097

ABSTRACT

The aim of this study was to evaluate the ability of the Penn-Century Dry Powder Insufflator for mice (DP-4M) to reproducibly, uniformly, and deeply deliver dry powders for inhalation in the mouse lung. Itraconazole-based dry powder formulations produced by spray-drying were different in terms of composition (different ratios of drug and mannitol, with or without phospholipids), but relatively similar in terms of particle size and mass median aerodynamic diameter. The ability of the dry powder insufflator to disaggregate each formulation was the same, indicated by the absence of a statistically significant difference between the particle size distribution parameters, as measured by laser scattering. The emitted fraction varied in vivo compared to the in vitro condition. Fluorescent particle distribution in the lungs was uniform and reached the alveolar spaces, as visualized by fluorescent microscopy. In terms of drug recovery in lung tissue, a minimum administered powder mass (in this case ∼1 mg) was necessary to recover at least 30% of the emitted dose in the lung and to obtain reproducible pulmonary concentrations. To reduce the dose administered in the lung, it was preferable to dilute the active ingredient within the carrier instead of reducing the dry powder mass inserted in the sampling chamber. Dry powder insufflators are devices usable in dose-dependent preclinical trials but have critical parameters to efficiently deliver reproducible doses depending on the type of formulation.


Subject(s)
Drug Delivery Systems , Dry Powder Inhalers , Itraconazole/administration & dosage , Lung/metabolism , Animals , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical/methods , Excipients/chemistry , Itraconazole/pharmacokinetics , Lasers , Male , Mannitol/chemistry , Mice , Mice, Inbred ICR , Microscopy, Fluorescence , Particle Size , Phospholipids/chemistry , Reproducibility of Results , Scattering, Radiation , Tissue Distribution
SELECTION OF CITATIONS
SEARCH DETAIL
...